Microdose, the global leader in B2B psychedelic intelligence, is pleased to be releasing the IP & Patents Report, a special communique spotlighting vital information regarding intellectual property and patentability of novel psychedelic drugs, delivery mechanisms, and more, compiled by leading experts in the field. This special report is free to access and the precursor to the upcoming investment-grade Psychedelic Industry Report, which will be launched at the end of the first financial quarter of the year.
The modern psychedelic renaissance has empirically proven that psychedelic drugs are going to revolutionize mental health treatment, disrupting the $100 billion dollar pharmaceutical industry. However, before these incredibly promising medicines can get to the people who need them the most, they must pass through the extensive drug development pipeline, where IP & Patents are crucial. Since the drug development pathway is considerably expensive, difficult and time-consuming, Microdose is pleased to provide this snapshot of the IP and patent landscape in psychedelic drug development for the psychedelic community. The report aims to inform policy discussions, strategic research, and drug development guidelines. The report may also be used to analyze the validity of patents based on data about their legal status.
Since patenting is one of the most important steps to bringing a new drug to market, this report provides an incredible opportunity for expanding one’s understanding of the drug development pathway. This free report details crucial information about how new psychedelic compounds can be patented and has been compiled by leading experts in this field.
In addition to this special, free-to-access IP & Patents report, Microdose is pleased to announce the upcoming launch of our signature Microdose Psychedelic Industry Report
. This investment-grade market intelligence guide will be launched at the end of quarter one this year in addition to our Psychedelic Industry Online Directory. In an effort to aid stakeholders within the emerging psychedelic industry, the Industry Report includes 10k+ industry data points and covers key insights, market data, sector fundamentals, transactions, clinical trials and important research pertaining to psychedelic medicine. Set to reach a massive audience of investors, clinicians and industry experts, this comprehensive Industry Report is sure to inspire and inform psychedelic medicine enthusiasts about the exciting renaissance that is currently underway.
Microdose is pleased to be collaborating with the leading companies in the psychedelic industry to create this comprehensive report as well as this special IP & Patents Report. Thank you to Zuber Lawler, Psilocybin Alpha, and Calyx Law for contributing content towards this important endeavor. Thank you to our sponsors who are featured in this report: MagicMed Industries, Zuber Lawler, Psygen, Mydecine Innovations Group, Numinus, & Universal Ibogaine. Through collaborations with thought leaders driving the psychedelic renaissance, we have been able to curate an important and relevant report for this emerging sector.
Sponsorship opportunities are still available for the full Psychedelic Industry Report; please contact Christina Cassen to discuss: christina@microdose.buzz.